Several commercial NIPT providers in the US said they are planning to participate in the new program.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
The deal is still subject to other closing requirements including meeting a minimum tender condition.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The firm, as indicated by its agreement to acquire Sequenom, is optimistic about the prospects for NIPT.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.